TNF and neoplasm: The first clinical trial (identifier: NCT00356980), which begun in 2006, involved Aurimune CYT-6091 (Cytimmune), the first tumor-targeted nanostructure consisting of 27 nm pegylated AuNPs conjugated with a tumor necrosis factor alpha (TNF).